Vaccine imports could cost $1.2b - Discover Hidden USA

Islamabad – Pakistan’s Health Minister, Mustafa Kamal, recently warned of a potential surge in the nation’s annual vaccine costs, reaching up to $1.2 billion by 2031, if domestic vaccine production is not established. Kamal described the current reliance on imported vaccines as a significant and growing economic burden for the country.

Growing Demand and Shifting Support

Pakistan, currently the world’s fifth most populous country with approximately 240 million people, sees around 6.2 million births each year. This high birth rate is driving increased demand for vaccines. Currently, the government provides 13 types of vaccines free of charge to its citizens, but none of these are manufactured within Pakistan.

Current Costs and Future Projections

The country currently spends approximately $400 million annually on vaccine imports. Of this amount, international partners cover 49%, while the Pakistani government funds the remaining 51%. However, this international support is slated to end after 2031. Without local production, costs are projected to rise dramatically.

Did You Know? Pakistan currently imports all of its vaccines, despite having a population of approximately 240 million and recording around 6.2 million births annually.

Kamal noted that vaccine procurement has historically been done through GAVI, the Global Alliance for Vaccines and Immunization, with supplies previously coming from India. However, he stated that this supply route has been disrupted following the May 2025 conflict.

Efforts Towards Self-Sufficiency

The government has already begun taking preparatory steps to establish local vaccine production, rather than waiting for international donor support to lapse. Kamal expressed Pakistan’s ambition to achieve self-sufficiency in vaccine production in the near future. He highlighted the examples of Saudi Arabia, which has been working on vaccine development for the past decade, and Indonesia, which currently produces two million doses annually.

Expert Insight: The potential loss of international funding and the disruption of existing supply chains create a critical need for Pakistan to develop its own vaccine manufacturing capabilities. Failure to do so could place a substantial strain on the national economy and public health system.

A possible next step for Pakistan is to continue and accelerate discussions with international partners, such as Saudi Arabia, to explore collaborative opportunities in vaccine production. Analysts expect that securing technology transfer and investment will be crucial for establishing a sustainable domestic industry. This proves also likely that the government will prioritize infrastructure development and workforce training to support local manufacturing.

Frequently Asked Questions

What is the current annual cost of vaccines for Pakistan?

The current annual cost of imported vaccines is approximately $400 million, with international partners covering 49% and the government covering 51%.

When is international funding for vaccines expected to end?

International assistance for vaccines is scheduled to end after 2031.

What is Pakistan doing to address this issue?

The government has begun preparatory work to establish local vaccine production and aims to achieve self-sufficiency in the near future.

As Pakistan navigates these challenges, what role might regional partnerships play in securing its future vaccine supply?